Abstract:Drug targeting is an active area of research and nano-scaled drug delivery systems hold tremendous potential for the treatment of neoplasms. In this study, a novel cyclodextrin (CD)-based nanoparticle drug delivery system has been assembled and characterized for the therapy of folate receptor-positive [FR(+)] cancer. Water-soluble folic acid (FA)-conjugated CD carriers (FACDs) were successfully synthesized and their structures were confirmed by 1D/2D nuclear magnetic resonance (NMR), matrix-assisted laser desorption ionization time-of-flight mass spectrometer (MALDI-TOF-MS), high performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR), and circular dichroism. Drug complexes of adamatane (Ada) and cytotoxic doxorubicin (Dox) with FACD were readily obtained by mixed solvent precipitation. The average size of FACD-Ada-Dox was 1.5–2.5 nm. The host-guest association constant K a was 1,639 M−1 as determined by induced circular dichroism and the hydrophilicity of the FACDs was greatly enhanced compared to unmodified CD. Cellular uptake and FR binding competitive experiments demonstrated an efficient and preferentially targeted delivery of Dox into FR-positive tumor cells and a sustained drug release profile was seen in vitro. The delivery of Dox into FR(+) cancer cells via endocytosis was observed by confocal microscopy and drug uptake of the targeted nanoparticles was 8-fold greater than that of non-targeted drug complexes. Our docking results suggest that FA, FACD and FACD-Ada-Dox could bind human hedgehog interacting protein that contains a FR domain. Mouse cardiomyocytes as well as fibroblast treated with FACD-Ada-Dox had significantly lower levels of reactive oxygen species, with increased content of glutathione and glutathione peroxidase activity, indicating a reduced potential for Dox-induced cardiotoxicity. These results indicate that the targeted drug complex possesses high drug association and sustained drug release properties with good biocompatibility and physiological stability. The novel FA-conjugated β-CD based drug complex might be promising as an anti-tumor treatment for FR(+) cancer.

Nitro-fatty acids: promising agents for the development of new cancer therapeutics

The Emerging Roles of Nitric Oxide in Ferroptosis and Pyroptosis of Tumor Cells.

A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer

Free Fatty Acid Receptors and Cancer: From Nutrition to Pharmacology

Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

Nitro fatty acids: A comprehensive review on analytical methods and levels in health and disease

Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer

Oncogenic signaling of the free-fatty acid receptors FFA1 and FFA4 in human breast carcinoma cells

PPARα Agonism Enhances Immune Response to Radiotherapy while Dietary Oleic Acid Results in Counteraction

Perspectives of the Application of Non-Steroidal Anti-Inflammatory Drugs in Cancer Therapy: Attempts to Overcome Their Unfavorable Side Effects

Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy

Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, Β-Cyclodextrin-based Drug Complexes for Cancer Treatment.

Fatty acid oxidation: An emerging facet of metabolic transformation in cancer

Nitric Oxide and S-Nitrosylation in Cancers: Emphasis on Breast Cancer

Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis.

Fatty Acid Synthase and Neoplasms Therapy

Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling

Nitrated Fatty Acids as Signaling Molecules

Omega-3 polyunsaturated fatty acids of fish and their role in cancerous cell lines: A review of in-vitro studies

Protein Phosphorylation in Cancer: Role of Nitric Oxide Signaling Pathway

Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy